Research
Hormonal
Resmetirom (80-100 mg daily) significantly improves MASH resolution and fibrosis regression in patients with F2-F3 fibrosis compared to placebo.
If you have moderate-to-advanced liver scarring from MASH, resmetirom is the first approved drug to help reverse it. Take 80mg or 100mg daily. Expect possible mild stomach issues, but serious risks are low. This targets the root hormonal imbalance driving liver fat.
GoodSupportsHIGH confidence
MASH resolution with no worsening of fibrosis was achieved by 25.9% of subjects in the 80 mg resmetirom arm, and 29.9% of subjects in the 100 mg resmetirom arm, compared with 9.7% of subjects in the placebo arm. Reduction of fibrosis by at least one stage with no worsening of the NAS was seen by 24.2% of subjects in the 80 mg arm and 25.9% of subjects in the 100 mg arm, compared with 14.2% of subjects in the placebo arm.
Why this rating
Based on a large, multi-center Phase 3 trial (MAESTRO-NASH) with biopsy-defined endpoints.
Source
Prospects of late-stage development agents in the treatment of metabolic dysfunction-associated steatohepatitis
Brian K. Lee et al. · Clinical and Molecular Hepatology · 2025
DOI 10.3350/cmh.2025.0337
narrative_reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (e.g., Semaglutide) improve MASH indirectly through weight loss and improved insulin resistance, as the liver lacks direct GLP-1 receptors.Good
- Lanifibranor (800-1200 mg daily) significantly improves MASH resolution and fibrosis regression in patients with noncirrhotic MASH compared to placebo.Moderate
- Saroglitazar (4 mg daily) significantly improves liver enzymes and liver fat content in patients with MASLD/MASH.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →